Growing evidence suggests that microRNAs (miRNAs) facilitate the cross-talk between transcriptional modules and signal transduction pathways. MYC and NOTCH1 contribute to the pathogenesis of lymphoid malignancies. NOTCH induces MYC, connecting two signaling programs that enhance oncogenicity. Here we show that this relationship is bidirectional and that MYC, via a miRNA intermediary, modulates NOTCH. MicroRNA-30a (miR-30a), a member of a family of miRNAs that are transcriptionally suppressed by MYC, directly binds to and inhibits NOTCH1 and NOTCH2 expression. Using a murine model and genetically modified human cell lines, we confirmed that miR-30a influences NOTCH expression in a MYC-dependent fashion. In turn, through genetic modulation, we demonstrated that intracellular NOTCH1 and NOTCH2, by inducing MYC, suppressed miR-30a. Conversely, pharmacological inhibition of NOTCH decreased MYC expression and ultimately de-repressed miR-30a. Examination of genetic models of gain and loss of miR-30a in diffuse large B-cell lymphoma (DLBCL) and T-acute lymphoblastic leukemia (T-ALL) cells suggested a tumor-suppressive role for this miRNA. Finally, the activity of the miR-30a-NOTCH-MYC loop was validated in primary DLBCL and T-ALL samples. These data define the presence of a miRNA-mediated regulatory circuitry that may modulate the oncogenic signals originating from NOTCH and MYC.
INTRODUCTION
The transcriptional factors MYC and NOTCH1 have critical role in the pathogenesis of B-and T-cell malignancies. 1, 2 Gain-of-function mutations in NOTCH1 are predominantly found in T-ALL (T-acute lymphoblastic leukemia), 3 but recent evidence implicate NOTCH1 and NOTCH2 also in subsets of mature B-cell malignancies. [4] [5] [6] [7] Likewise, despite the fact that MYC is more prominently linked to B-cell lymphoma biology, its relevance to T-ALL pathogenesis is well established, at least in part due to NOTCH1's ability to induce MYC expression. [8] [9] [10] This interplay extends to other members of the NOTCH pathway, and NOTCH2 also transcriptionally induce MYC. 11 Conversely, it remains unclear whether MYC also positively regulates NOTCH expression/activity, a potentially beneficial mechanism to sustain the signals originating from these oncogenes. However, as concrete evidence for direct transcriptional regulation of NOTCH1 and NOTCH2 by MYC is lacking, [12] [13] [14] if such regulatory node exists, it would probably involve intermediaries.
MicroRNAs (miRNAs) are ideal candidates to mediate the potential effect of MYC activity on NOTCH expression. Indeed, growing evidence suggests that these non-coding RNAs are often the key elements in facilitating the cross-talk between transcriptional modules and pathways. 15, 16 Furthermore, while data from multiple cell models suggested that MYC functions as a master regulator of miRNA expression, 1, 17 the full scope of miRNA dysfunction in lymphoid malignancies remains to be defined. 18 Thus identification of a miRNA that may bridge the oncogenic MYC and NOTCH nodes could improve our understanding of the pathogenesis of these disorders.
To investigate this concept, we considered miRNAs that we had earlier reported to display aberrant copy number/expression in diffuse large B-cell lymphomas (DLBCL) 19 and that were independently shown to be directly regulated by MYC. 17 This approach identified the miRNA-30 family as a candidate for a putative MYCdependent regulation of NOTCH1 and NOTCH2 expression. We focused on microRNA-30a (miR-30a) to validate this interplay, as among the members of the miR-30 family it had the less well-characterized interaction with MYC and the NOTCH pathway, 17, 20, 21 thus assuring that our findings would add new knowledge to the field.
Herein, we confirmed that MYC negatively influences miR-30a expression and discovered that this miRNA directly targets NOTCH1 and NOTCH2. Using genetic and pharmacological models, we characterized a regulatory loop, whereby the MYCmediated inhibition of miR-30a de-represses NOTCH, eventually modulating its own expression. Further, we showed that miR-30a altered the fitness of B-and T-cell malignancies, consistent with a tumor-suppressive role. Finally, to determine the relevance of this finding beyond genetically engineered cell models, we examined primary human tumors and found a significant correlation between the expression of miR-30a and NOTCH2 in DLBCL and between NOTCH1 mutational status and miR-30a expression in T-ALLs.
MATERIALS AND METHODS
Cell lines and primary tumors DLBCL cell lines (SU-DHL6, SU-DHL7 and OCI-Ly18) and T-ALL cell lines (DND-41 and KOPT-K1) were cultured at 37°C in 5% CO 2 in RPMI-1640 medium containing 10% (vol/vol) fetal bovine serum, penicillin (100 units/ ml), streptomycin (100 μg/ml), Hepes buffer (10 mmol/l) and L-glutamine (600 μg/ml). HEK-293 cells were maintained in Dulbecco's modified Eagle medium with 10% fetal bovine serum. Sixteen primary DLBCL specimens were obtained from our local tumor bank, as reported earlier. 19 Five primary T-ALL samples obtained from the Division of Hematology, Medical University of Graz, Graz, Austria. The clinical and pathological features of these tumors are summarized in Supplementary Tables S1 and S2. The use of primary tumor samples was approved by the Review Boards of the UTHSCSA, USA and Medical University of Graz, Austria and conforms to the Declaration of Helsinki.
Mice and isolation or murine mature splenic B lymphocytes
Eμ-Myc transgenic male mice (Myc Tg+/ − ) on a C57BL/6 background (B6.Cg-Tg[IgHMyc]22Bri/J) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and maintained by in-house breeding with C57BL/6 female mice to generate Myc Tg+/ − and C57BL/6 (wild-type (WT)) littermates. Five-to-14-week-old sex-matched WT and Myc Tg+/ − mice littermates (all without clinical evidence of lymphoma) were euthanized, and their splenic B cells purified using the mouse B-Cell Enrichment kit (StemCell Technologies, Vancouver, BC, Canada), as we described earlier. 22 The purity and degree of enrichment was determined by FACS (fluorescence-activated cell sorter)-based measurement of CD19-positive cells, in preseparation and postseparation aliquots-the fraction of CD19positive cells was 495%. All animal procedures were approved by the Institute Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Lucifererase reporter assays
Three PCR-generated fragments containing the miR-30a binding sites (one in NOTCH1, two in NOTCH2) (Supplementary Figure S1 ) were individually cloned in the 3′ untranslated region (UTR) of the luciferease gene (pMIR vector, Ambion, Austin, TX, USA). Site-directed mutagenesis was used to modify three of the six 'seed sequence' nucleotides in each construct, as we described. 23 After sequencing verification, these constructs were cotransfected in HEK-293 cells with the pCMVβ-gal plasmid (5 ng) and 100 nM each of chemically synthesized pre-miR-30a or pre-miR negative control oligonucleotides (Sigma, St Louis, MO, USA). Cells were harvested 48 h after transfection, and luciferase and β-galactosidase activities measured, as we described. 24 The primers sequences are listed in Supplementary Table S3 .
Generation of stable genetic models of miR-30a and NOTCH
A fragment of ∼ 600 bp encompassing the precursor miR-30a sequence was PCR amplified, sequence verified and cloned into the MSCV-eGFP (murine stem cell virus-enhanced green fluorescent protein) retrovirus vector, as we described. 24 Intracellular NOTCH1 and NOTCH2 (ICN1 and ICN2, respectively) were subcloned from pCDNA3 into MSCV-eGFP to generate MSCV-ICN1 and MSCV-ICN2, respectively. To produce a miR-30aspecific sponge construct, sense and antisense oligonucleotides containing two mature miRNA-30a sequences separated by a short 'spacer' were synthesized and annealed, as reported earlier, 25 and cloned in tandem in the 3′UTR of the eGFP gene (pEGFP-C3 plasmid, Clontech, Mountain View, CA, USA). The sponge sequences included bulged sites ( Supplementary  Table S3 ) located just after the seed sequence (nucleotides 9-12) promoting a mispairing and thus forming more stable interactions with the miRNA. A construct containing six mature miR-30a complementary repeats arranged in tandem in the 3′UTR of eGFP was used for downstream studies. A control sponge, containing a scrambled sequence that does not match any human miRNA was similarly designed and cloned. It should be noted that due to the similarity between the members of the miR-30 family, we cannot exclude the possibility that some of effects derived from the expression of the miR-30a-sponge construct stem from the functional sequestration of other members of this miRNA family. Cell models stably expressing MSCV-miR-30a, MSCV-ICN1, MSCV-ICN2 or an empty MSCV vector were created by retrovirus transduction and sorting of eGFP-positive cells to high purity (495%), as we described. 26 The cell lines stably expressing the sponge plasmids (miR-30a or scrambled) were generated by electroporation, followed by antibiotic (G418) selection and eGFP-based cell sorting. The direct interaction between miR-30a and NOTCH1 was examined by electroporating T-ALL cells with 125 nM of an antisense oligonucleotide (5′-TGTAAACTACACTCTATT-3′) (Exiqon, Woburn, MA, USA) that binds to the miR-30a site on NOTCH1 3′UTR, thus preventing this miRNA from gaining access to the mRNA.
Immunoblotting
Whole-cell lysates were extracted, separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane, as we described. 27 For detection of relevant proteins, the following antibodies were used: c-MYC (Santa Cruz, sc-40, Dallas, TX, USA), NOTCH1 (Santa Cruz, sc-32745), NOTCH2 (Cell Signaling, no. 5732S, Danvers, MA, USA), cleaved NOTCH1 (val1744) (Cell Signaling, no. 2421S), cleaved Caspase-3 (Asp175), and Caspase 3 (Cell Signaling, nos. 9661 and 9662). The membranes were stripped with OneMinute Western Blot Stripping Buffer (GM Biosciences, Rockville, MD, USA) and re-probed with anti-β-actin antibody (Sigma-Aldrich, no. A2228, St Louis, MO, USA).
In Vitro drug treatments DND-41 and KOPT-K1 cells were exposed to 100 nM or 200 nM of the gamma-secretase inhibitor (GSI) Compound E (Enzo Life Sciences, Inc., Farmingdale, NY, USA) or dimethyl sulfoxide control for 24, 48 and 72 h. Subsequently, cells were harvested for RNA-and protein-based analyses. All experiments were validated in two to three biological replicates.
Cell growth, cell cycle and apoptosis analyses
The growth pattern of the genetically modified T-ALL cell lines and isogenic controls was defined by plating the cells at equal density (0.6-1 × 10 5 cells/ml) in fresh media (Day 0), in triplicate. Cell number and viability were determined daily by an automated trypan blue exclusion assay (Cellometer Vision CBA system, Nexcelom, Lawrence, MA, USA) and side-by-side manual counting (Neubauer chamber). At Day 5, these cells were also analyzed for cell cycle distribution and apoptosis, using propidium iodide (PI) and Annexin V staining, respectively, followed by FACS analyses, as we described. 24 The growth pattern of electroporated T-ALL cell lines was defined by plating viable cells 24 h after electroporation at equal density (1 × 10 5 cells/ml) in fresh media (Day 0), in triplicate. Cell number and viability were determined at 48-and 72-h postelectroporation by an automated trypan blue exclusion assay and sideby-side manual counting. In the DLBCL cell lines expressing scramble or miR-30a-specific sponges, apoptosis was measured in response to oxidative or starvation stresses. In brief, cells were grown in serum-free media or in the presence of 25 μM of H202 (Sigma) for 48 h (10% serumcontaining media and dimethyl sulfoxide as controls, respectively) and FACS-based Annexin V staining (PE Annexin V Apoptosis Detection Kit I; BD Pharmingen, San Jose, CA, USA) was used to determine apoptosis rate. All experiments were validated in two to three biological replicates.
Quantification of miR-30 expression
Relative expression of miR-30a, -30b, -30c, -30d and -30e was defined by stem-loop quantitative TaqMan real-time reverse transcription PCR (RT-PCR) assay (MicroRNA assays; Applied Biosystems Inc., Grand Island, NY, USA), as we reported previously. 28 Small Nucleolar (Sno) RNA-202 and Sno RNA U18 were used for normalizing the expression in murine and human cells, respectively.
Sanger sequencing
High molecular weight genomic DNA was isolated from five primary T-ALL samples using the Gentra Puregene DNA purification kit (Qiagen, Valencia, CA, USA). DNA (50 ng) was PCR amplified for 40 cycles for regions spanning mutational hot-spots in NOTCH1, exons 26, 27 and 34. Amplicons were verified on agarose gel and bi-directionally sequenced, and results were analyzed using the Mutation Surveyor software (Softgenetics, State College, PA, USA).
Statistics
The Mann-Whitney test was used to determine the significance of the difference in NOTCH2 expression in primary DLBCL dichotomized by low An oncogenic MYC-miR-30-NOTCH circuitry M Ortega et al and high miR-30a expression. Significance of the differences in miR-30a expression in primary T-ALL and T-ALL cell lines was tested with one-way analysis of variance. For all other assays, the statistical analyses were performed with two-tailed Student's t-test. P o0.05 was considered significant. Data analyses were performed in the Prism software (version 5.0; GraphPad, La Jolla, CA, USA) and Excel software (Microsoft, Seattle, WA, USA).
RESULTS
Functional binding sites for miR-30a are present in the 3′UTRs of NOTCH1 and NOTCH2 Earlier, we reported on miRNAs that displayed aberrant copy number and expression in DLBCL. 19 Independently, a subset of these miRNAs, including the miR-30 family, was shown to be directly regulated by MYC. 17 Here, we centered our investigations on miR-30a as the prediction algorithm TargetScan (Release 6.2) 29 identified NOTCH1 and NOTCH2 as high confidence candidate targets for this miRNA. Further, among the members of the miR-30 family, miR-30a had the less well-characterized interaction with MYC and the NOTCH pathway, 17, 20, 21 therefore assuring that our findings would add new knowledge to the field. A single highly conserved miR-30a binding site was predicted in the 3′UTR of NOTCH1 and two non-conserved sites in the 3UTR of NOTCH2 (Supplementary Figure S1 ). To test their functionality, we used prototypical reporter assays, whereby DNA fragments containing each of three sites are cloned in the 3′UTR of the luciferase reporter gene, as described. 23 To ascertain the specificity of these miRNA/target gene interactions, for each site we also created constructs containing three interposed point mutations in the seed-sequence (miRNA's nucleotides 2-7) disrupting the putative binding sites. Expression of miR-30a resulted in significant suppression of the luciferase activity in all three seed-sequence WT constructs (corresponding to one NOTCH1 and both NOTCH2 sites, P o 0.05, Student's t-test), whereas miR-30a had no effect towards the mutant constructs ( Figure 1a ). These data indicate that miR-30a directly binds to NOTCH1's and NOTCH2's 3′UTRs and may inhibit their expression.
Genetic modulation of miR-30a impinges on NOTCH1 and NOTCH2 expression
To define whether the binding of miR-30a to the 3′UTRs of NOTCH1 and NOTCH2 inhibited their expression, we generated a panel of four cell lines-two DLBCL (SU-DHL6 and SU-DHL7) and two T-ALL (KOPT-K1 and DND-41)-stably expressing miR-30a from a retrovirus system (MSCV-eGFP), as described 24 (Supplementary Figure S2 ). Note that we purposely selected to use NOTCH1-mutant T-ALL cell lines is this study, for we suggest that it is in this context that the relevance of miR-30a suppression to the pathogenesis of this disorder may be better demonstrated. In both disease models, expression of miR-30a suppressed NOTCH1 and NOTCH2 expression ( Figure 1b ). In the NOTCH1 mutant T-ALL cell lines, the miR-30a effects were also readily detected upon examination of the NOTCH1 intracellular domain with an antibody that recognizes the Val1744 position (cleaved NOTCH1). To expand this observation to loss-of-function models, we used a miR-30a-specific sponge construct, an elaborate model of functional depletion of miRNAs that provides stable competitive titration of these small non-coding RNA from their targeting sites. 25 The activity and specificity of the 'sponge constructs' was confirmed by its ability to abrogate the effects of miR-30a in the NOTCH1 binding-site luciferase reporter assay (Supplementary Figure S3 ). Again, a panel of four cell lines-two DLBCL (SU-DHL7 and OCI-Ly18) and two T-ALL (KOPT-K1 and DND-41)-were generated with stable expression of sponge constructs directed at miR-30a or a scrambled sequence. Of note, repeated attempts to create SU-DHL6 stably expressing miR-30a-sponge were unsuccessful. Thus we used a related GCB-like DLBCL cell line (OCI-Ly18) to create the fourth loss-of-function model, guaranteeing the representative nature of our observations. In agreement with the overexpression model, sequestering miR-30a away from its target genes with 'sponges' resulted in an increase in NOTCH1 and NOTCH2 expression ( Figure 1c ). As expected, in the DLBCL cell lines NOTCH2 was more consistently expressed than NOTCH1, suggesting that the former is the principal biological target of miR-30a in mature B-cell tumors. Finally, as we indicated earlier, the use of NOTCH-1 mutant T-ALL cell lines was important for it allowed us to show that a miRNA can modulate the expression (Figures 1b and c) , and function (see below), of constitutively active NOTCH1, a finding that may eventually have therapeutic implications. Indirectly, our data also suggest that the suppression of miR-30a (see below) may be an important component of mutant-NOTCH1's transcriptional activity.
MYC regulates and it is regulated by the miR-30a-NOTCH1/2 axis The data shown above confirm that miR-30a directly suppress NOTCH1 and NOTCH2 expression. As MYC has been reported to suppress the expression of the miR-30 family by directly binding to their promoters (defined by chromatin immunoprecipitation-PCR), 17 we tested whether modulating MYC levels/activity altered the levels of miR-30a in our models and, consequently, NOTCH1 and NOTCH2. To that end, we first (Figure 2a ). Next, we used western blotting to examine the expression of NOTCH1 and NOTCH2 in these cells and found that NOTCH1 levels were higher in B cells from the MYC Tg mice (Figure 2a ) than from the WT mice, presumably, at least in part, due to the lower expression levels of miR-30a. Supporting the role of miR-30a in regulating this process, no change in the expression of NOTCH2 was found in this model, which we attribute to the lack of conservation of the NOTCH2 miR-30a binding sites in the mouse genome (Supplementary Figure S1) . Thus MYC appears to suppress miR-30a expression and consequently impinge on NOTCH levels. We next considered the reverse, that is, the role of miR-30a in the regulation of MYC; we reasoned that if the regulatory circuitry that we are describing is a 'closed loop', then not only will MYC suppress miR-30a but also will miR-30a by modulating the NOTCH expression eventually affect MYC levels. Indeed, examining the miR-30a gain-or loss-of-function models generated in DLBCL and T-ALL cell lines, we found that suppression of NOTCH1 and NOTCH2 by miR-30a ( Figure 1b ) was associated with inhibition of MYC expression (Figure 2b, top) . Conversely, the functional depletion of miR-30a by the 'sponge' construct increased MYC expression ( Figure 2b, bottom) , probably as a consequence of the NOTCH1 and/or NOTCH2 de-repression in these cells (Figure 1b) ; at present, we cannot fully exclude the possibility that other, still uncharacterized, miR-30a targets also contribute to modulation of MYC found in our cell models.
Genetic and pharmacological modulation of NOTCH1 and NOTCH2 modifies miR-30a expression We showed above that the modulation of the MYC/miR-30a axis interferes with the NOTCH1 and NOTCH2 expression. Next, we attempted to isolate the role of NOTCH in this circuitry. To achieve this goal, we first stably expressed constitutively active NOTCH1 and NOTCH2 constructs (ICN1 and ICN2, respectively) in the DLBCL cell line SU-DHL7. Using western blotting, we confirmed the expression of ICN1 or ICN2 in these cells and demonstrated the consequent induction of MYC (Figure 3a ). Then we measured miR-30a expression in these cells and found it to be significantly lower in ICN1-and ICN2-positive than in the SU-DHL7-MSCV control cells (P o 0.05, two-sided Student's t-test) (Figure 3a ). In complementary assays, we exposed NOTCH1-mutant T-ALL cell lines to a GSI, Compound E, and determined the temporal relationship between ICN1 inhibition, MYC suppression and miR-30a modulation. In these assays, ICN1 showed early and sustained inhibition, which was followed by MYC downregulation and finally (as expected) miR-30a de-repression (an~50% increase in its expression at 72 h) ( Figure 3b ). It is important to note that with these genetic and pharmacological models (Figures 3a and b , respectively) we did not expect to find a massive modulation (suppression or induction, respectively) of miR-30a. Surely, as any other gene, miR-30a's transcriptional regulation is controlled by other mechanisms, which presumably remain intact in our models. The central purpose of these assays was to demonstrate that positive and negative perturbations of NOTCH1/2 activity eventually leads to miR-30a downregulation and upregulation, respectively, which our data suggest occurs via MYC. Finally, as MYC has been reported to repress the expression of other members of the miR-30 family, we tested whether the genetic and/or pharmacological modulation of NOTCH1 would broadly impact on miR-30 expression. Indeed, ectopic expression of ICN1 suppressed, whereas exposure to Compound E de-repressed the expression of multiple members of this miRNA family (Supplementary Figure S4) . These data suggest that the network of genes impinged upon by the NOTCH-MYC-miR-30 circuitry expands beyond the miR-30a targets.
MiR-30a has tumor-suppressive properties towards T-ALL and DLBCL cell lines The data above, established the presence of a regulatory loop that when engaged by activation of either NOTCH or MYC could result in modulation of their own and each other's expression, at least in part via the suppression of miR-30a. It follows that miR-30a expression could disrupt the growth advantage provided by oncogenic NOTCH and MYC. To test this possibility, we first examined the effects of stably expressing miR-30a in NOTCH1mutant T-ALL cell lines. In both models, we found a significant decrease in the growth rate of miR-30a-expressing cells when compared with their isogenic controls expressing an empty MSCV vector -an~32-50% suppression in DND-41 and KOPT-K1 growth (P o 0.01 two-sided Student's t-test, Figure 4a and Supplementary Figure S5 ). MiRNAs target multiple mRNAs. Thus, to confirm that the observed growth suppression resulted from the direct effects of miR-30a towards NOTCH1, we used an antisense oligonucleotide (target site blocker) that blocked the access of this miRNA to its binding site on NOTCH1's 3′UTR. In these assays, the target site blocker oligonucleotide was electroporated into a T-ALL cell line stably expressing MSCV-miR-30a, alongside mock-electroporated empty MSCV and miR-30a cells. Subsequently, viable cells were plated at equal density and growth pattern was defined at 48 and 72 h posttransfection, accompanied by western blotting analysis of NOTCH1 expression. As shown in Figure 4b , blocking miR-30a targeting of NOTCH1 restored the growth rate of the miR-30aexpressing cells to the levels of their isogenic MSCV-only controls, in association with de-repression of NOTCH1 expression. In agreement with these observations, and to demonstrate that these are not exclusive features of an overexpression model, we found that the functional depletion of miR-30a with the sponge construct enhanced the fitness of the cells as they grew at a significantly faster pace than isogenic cells expressing a scrambled sponge-an~40% increase in DND-41 and KOPT-K1 cell numbers (P o 0.01, two-sided Student's t-test, Figure 4b and Supplementary   ICN1   ICN2   MYC   β-actin   MSCV  ICN1  ICN2   GSI  GSI  GSI  DMSO  DMSO  DMSO  GSI  GSI  GSI   24h An oncogenic MYC-miR-30-NOTCH circuitry Figure S5 ). Cell cycle arrest and/or apoptosis probably accounts for the significantly slower growth pattern found in miR-30aoverexpressing cells (Supplementary Figure S5) , similarly to the reported effects of GSI in NOTCH1 mutant cell lines. 30, 31 The heightened apoptosis rate of the miR-30a-expressing cells was confirmed by Annexin V staining (Supplementary Figure S6) , as well as by cleaved caspase-3 western blotting (Supplementary Figure S7 ). Contrary to the NOTCH1-mutant T-ALL cell lines, ectopic expression of miR-30a or its sponge-mediated depletion did not immediately alter the growth pattern of genetically modified DLBCL cell lines, perhaps suggesting that miR-30a have a more dominant role in the context of NOTCH1 activation. Nonetheless, upon challenging these cells with serum starvation and H202-induced oxidative stress, which attempts to reflect the actual tumor microenvironment and recapitulate the effects of chemotherapy, 32 we consistently found that depletion of miR-30a rendered DLBCLs significantly more resistant to apoptosis induced by these signals (an~25-100% change, depending on the cell type and stimulus) (Figure 4c ). The lower apoptosis rate of the cells expressing miR-30a-sponge was confirmed by Annexin V staining (Figure 4c ), as well as cleaved caspase-3 western blotting (Supplementary Figure S7) . Of note, miRNAs are primarily fine tuners of gene expression, [15] [16] [17] and many other programs regulate NOTCH and MYC expression. In agreement with this concept, in all genetic models of miR-30a gain-or loss-of-function that we generated, residual expression of NOTCH1, NOTCH2 and MYC was present. Thus, as we showed in Figure 4a , marked and significant but not a complete disruption of cell proliferation and/or apoptosis is the expected outcome of modulating miR-30a in DLBCL and T-ALL cell lines.
MiR-30a expression correlates with NOTCH1 and NOTCH2 status in primary T-ALL and DLBCL biopsies
To verify whether the regulatory circuitry involving miR-30a and NOTCH1 or NOTCH2 was active in primary samples, we studied cohorts of T-ALL and DLBCL, respectively. First, we obtained highquality DNA and RNA from five T-ALL samples not previously characterized for their NOTCH1 mutational status. Sequencing of exons 26, 27 and 34 identified two samples as NOTCH1-WT and three with typical missense mutations targeting the heterodimerization mutation, alone or combined with truncating variants in the PEST (proline, glutamic acid, serine and threonine) domain ( Supplementary Table S1 ). Next, we used a stem-loop real-time The growth pattern of two NOTCH1-mutant T-ALL cell lines stably expressing miR-30a or an empty vector (MSCV) was monitored using an automated trypan blue exclusion assay (Cellometer Vision CBA system, Nexcelom). In both models, miR-30a expression significantly reduced cell proliferation (32% and 50% decrease in DND-41 and KOPT-K1, respectively; **Po 0.01, two-tailed Student's t-test). (b) DND-41 cells stably expressing MSCV or miR-30a were mock-transfected or transfected with a target site blocker (TSB) oligonucleotide. In mock-transfected cells, miR-30a expression significantly repressed cell growth (**P o0.01, two-tailed Student's t-test), whereas these effects were lost in cells transfected with the NOTCH1-miR-30a TSB (NS = nonsignificant). TSB-transfected miR-30a-expressing cells also showed significantly higher growth rate than their isogenic mock-transfected miR-30a counterparts. Western blotting confirms the NOTCH1 de-repression in cells exposed to the TSB oligonucleotide. (c) Functional inactivation of miR-30a with stable expression of a specific sponge construct significantly enhanced the growth rate of the T-ALL cells (añ 40% increase in DND-41 and KOPT-K1 at day 5; **Po0.01, two-tailed Student's t-test). (d) In the DLBCL model, sequestering miR-30a from its targets with a sponge construct rendered these cells significantly more resistant to apoptosis induced by broadly genotoxic stresses, starvation (0% serum) or oxidation (H202, 25 μM) for 24 or 48 h (**P o0.01, two-tailed Student's t-test). Control and 10% serum indicate the basal apoptosis rate in cells exposed to vehicle or grown in full media. All data shown are mean ± s.d. of an assay performed in triplicate. Two to three biological replicates of each assay were completed, each time in triplicate.
RT-PCR assay to quantify miR-30a in these samples, alongside with the NOTCH1 mutant T-ALL cell lines. In agreement with the NOTCH-MYC-miR-30a axis that we are reporting on, we hypothesized that miR-30a expression would be lower in NOTCH1 mutant T-ALLs. Indeed, in this small cohort, we found that in primary T-ALLs NOTCH1 mutational status correlated well with miR-30a expression ( Figure 5a ) and that as a group the NOTCH1mutant T-ALL cell lines expressed the lowest levels of this miRNA, perhaps owing to their more homogenous cell population. We also examined the relationship between miR-30a and NOTCH in primary DLBCL biopsies, focusing on NOTCH2 given its more prominent role in mature B-cell biology. Here, we collected 16 primary DLBCL biopsies for which good-quality RNA and protein were available; this cohort was also enriched for samples that displayed only limited (o 10%) T-cell infiltrates, thus favoring a more precise analysis of the tumor cells with minor influence of the infiltrating non-malignant cells. Quantification of miR-30a in these DLBCLs revealed a broad continuum of relative expression (mean 3.11, range 0.2-26.5). Next, we investigated NOTCH2 expression in all 16 samples and grouped the 8 DLBCLs with the highest and the 8 with the lowest miR-30a levels (median relative expression 2.9 vs 0.7, respectively) for analysis. As shown in Figure 5b , expression of NOTCH2 significantly correlated with miR-30a levels, and it was markedly higher in tumors expressing low levels of this miRNA (P o 0.01, Mann-Whitney test). We also sequenced NOTCH2 in 11 of the 16 DLBCLs analyzed, as part of a larger next-generation sequencing project (not shown) and found it to be in WT configuration (mean coverage for the NOTCH2 locus in the 11 samples = 35 × , range 23-58 × ). These data suggest that the regulatory loop that includes NOTCH and miR-30a is active in the two distinct primary neoplasms and that this circuitry may contribute to the oncogenic thrust of these malignancies. Our ability to identify a significant correlation between NOTCH and miR-30a, despite the fact that these transcription factors are regulated by multiple inputs, highlights the relevance of this miR-30-dependent axis in B-and T-cell biology.
DISCUSSION
In this report, we identified and characterized a regulatory loop that includes miR-30a, NOTCH1 or NOTCH2 and MYC. In particular, our findings suggest that the earlier picture, that is, that NOTCH induces MYC, [8] [9] [10] was incomplete and that the relationship between these transcriptional programs is bidirectional, for MYC, by suppressing miR-30a, also impinges on NOTCH expression. Certainly, a full grasp of the relative contribution of this circuitry to NOTCH function, in normal and malignant settings, awaits the development of genetically engineered mice with specific disruption of the miR-30a binding site in NOTCH1 and NOTCH2.
Nonetheless, our cell models and initial analysis of primary samples suggest that miR-30a may have a part in regulating NOTCH and MYC signals. Conceivably, in T-ALLs with mutant NOTCH1, MYC upregulation could lead to miR-30a suppression and, secondarily, NOTCH1 de-repression. This regulatory loop could also start at the 'MYC position' leading first to miR-30a suppression, followed by NOTCH1 and NOTCH2 de-repression, which upon NOTCH ligand exposure could further induce MYC expression and activity. This concept is supported by our in vitro data; however, we fully recognize that, as it is the case with any other complex transcriptional program, multiple factors influence the expression and activity of all players identified herein (MYC, miR-30a and NOTCH). Thus the most robust messages from our findings are that MYC can indirectly modulate NOTCH1/2 levels via miR-30a, that in the examined in vitro models miR-30a has tumorsuppressive properties and that in primary tumors a correlation is found between miR-30a levels and NOTCH1/2 mutational status/expression. To determine whether miR-30a is a central modulator of NOTCH and MYC oncogenicity, it will require the development and characterization of new genetically engineered mice models; in this regard, we suggest that, with all its limitations, 33 Figure 5 . The miR-30a/NOTCH regulatory axis is active primary tumors. (a) Quantification of miR-30a in a cohort of five primary T-ALLs revealed lower miR-30a expression in NOTCH1 mutant than WT samples. Data shown are relative expression of miR-30a for each sample (and mean for the group), measured in triplicate and normalized by the levels of the small nucleolar RNA U18 (P = 0.56, one-way analysis of variance, P o0.05 Dunnett's multiple comparison test, WT samples vs mutant cell lines). (b) NOTCH2 levels defined by western blotting were significantly higher in primary DLBCL biopsies with low miR-30a expression (P o0.05, two-sided Mann-Whitney test for the densitometric values-shown in the lower left panel). Expression of miR-30a in these samples is shown on the lower right panel (P o0.05, two-sided Mann-Whitney test) and depicts the relative expression for each sample (and mean of the group) quantified in triplicate and normalized by the levels of the small nucleolar RNA U18.
lymphoma, and DLBCL. [4] [5] [6] 34 Characteristically, these mutations target the protein's PEST domains resulting primarily in their overexpression. Our data, in genetically modified cell lines and primary DLBCL biopsies suggest that miR-30a downregulation could also upregulate NOTCH1 and NOTCH2 in B-cell malignancies. Thus, as aberrant MYC activation is a frequent event in the pathogenesis of various B-and T-cell malignancies, and MYC suppresses miR-30a, abnormally high levels of NOTCH1 and NOTCH2 may be a more common component in the pathogenesis of these tumors than previously appreciated. In NOTCH1 mutant T-ALLs, the MYC-miR-30a-NOTCH axis that we described may primarily function to maintain an uninterrupted flux of the oncogenic signals between MYC and NOTCH, via downregulation of miR-30a. Approximately 20% of T-ALLs also have mutations in the ubiquitin ligase FBXW7. 35, 36 Interestingly, recent evidence suggests that the central consequence of a common FBXW7 mutation (R465C) is MYC stabilization. 35 Thus a scenario could be envisioned whereby in T-ALLs with FBXW7 mutations the higher levels of NOTCH derive both from its deficient degradation (that is, stabilization) and its de-repression secondary to the MYC-mediated miR-30a suppression.
Interestingly, a broader interaction between the miR-30 family and the NOTCH pathway may exist. Recent reports demonstrated that miR-30a, -30b and -30c directly inhibit the NOTCH ligand Delta-like 4 in endothelial cells. 37, 38 Furthermore, miR-30b was shown to target NOTCH1 in hematopoietic stem cells, while miR-30c regulates NOTCH1 expression in the human and murine myeloid cell compartment. 20, 21 Thus it is possible that other members of this miRNA family may also have a role in the circuitry that we identified herein, as suggested by the preliminary quantification of miR-30b-e in the ICN1-expressing and GSItreated models. More importantly, however, by specifically expressing miR-30a, we confirmed that this miRNA can independently influence the NOTCH-MYC regulatory loop. Our data add knowledge to the emerging relationship between the miR-30 family and the NOTCH pathway in two ways: we demonstrated that miR-30a targets NOTCH1 in human and murine lymphocytes and showed that NOTCH2 is also a target of miR-30a.
In summary, in this report we showed that the relationship between NOTCH and MYC is bidirectional and that, in addition to the earlier evidence that NOTCH induces MYC, [8] [9] [10] MYC itself, by suppressing miR-30a, also impinges on NOTCH expression. These observations may prove relevant to the pathogenesis of multiple neoplasms that rely on MYC and NOTCH signals for initiation and maintenance, and future examination of large and wellcharacterized cohorts of patients with mature follow-up should help define if this interplay has important clinical implications.
